Rakuoilia Pharmaceutical announced the addition of new indications for the gastric acid suppressant tegoprazan in South Korea through licensed partner HK Innoen. As of April 2026, South Korean sales reached approximately 110 billion yen, maintaining the market share at No.1.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4579","jir_company_name":"Rakuoilia Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4579-20260727-01.pdf","jir_short_summary":"Rakuoilia Pharmaceutical announced the addition of new indications for the gastric acid suppressant tegoprazan in South Korea through licensed partner HK Innoen. As of April 2026, South Korean sales reached approximately 110 billion yen, maintaining the market share at No.1.","jir_summary":"### Performance Overview\nRakuoilia Pharmaceutical announced the addition of indications for the gastric acid suppressant tegoprazan in South Korea via its licensing partner HK Innoen. The newly approved indication is for the prevention of digestive ulcers related to NSAID use, bringing the total indications in the South Korean market to six. As of April 2026, sales in South Korea reached approximately 110 billion yen, maintaining the market share at No.1. The company has expressed its intention to continue expanding its presence in the South Korean market and to enhance long-term corporate value.\n\n### Future Outlook and Investor Impact\nThe addition of indications in South Korea is expected to expand tegoprazan\u2019s market and strengthen its revenue base. Rakuoilia Pharmaceutical plans to further reinforce its collaboration with HK Innoen, promote new indications, and enhance sales. This is anticipated to lead to long-term revenue growth and increase corporate value, making it an attractive growth factor for investors.","jir_financial_highlights":"Domestic sales in South Korea: approximately 110 billion yen (unknown)\nNumber of indications in South Korea: 6 (Newly added prevention of digestive ulcers associated with NSAID use)\nYear of market launch in South Korea: 2019 (unknown)","jir_category":"","jir_hashtags":"#RakuoiliaPharmaceutical, #IR, #JapaneseStocks","jir_key_figures":"Domestic sales in South Korea: approximately 110 billion yen (as of April 2026)\nNumber of indications: 6 (including the newly added prevention of digestive ulcers related to NSAID use)\nMarket launch year: 2019","jir_meta_title":"\u3010Rakuoilia Pharmaceutical\u3011Addition of New Indications for tegoprazan in South Korea\uff5cJuly 2026","jir_meta_description":"Rakuoilia Pharmaceutical announced the addition of indications for tegoprazan in South Korea. As of April 2026, sales reached approximately 110 billion yen, maintaining the market share at No.1. Future prospects are keenly anticipated.","jir_og_title":"\u3010Rakuoilia Pharmaceutical\u3011Addition of Indications in South Korea\uff5cJuly 2026","jir_og_description":"Rakuoilia Pharmaceutical announced the addition of indications for tegoprazan in South Korea. With sales of approximately 110 billion yen and maintaining the No.1 market share, growth prospects are promising.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57587,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-88475","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n